CN104602708B - 痴呆症治疗药或预防药 - Google Patents

痴呆症治疗药或预防药 Download PDF

Info

Publication number
CN104602708B
CN104602708B CN201380040658.9A CN201380040658A CN104602708B CN 104602708 B CN104602708 B CN 104602708B CN 201380040658 A CN201380040658 A CN 201380040658A CN 104602708 B CN104602708 B CN 104602708B
Authority
CN
China
Prior art keywords
seq
sequence shown
cdr
antibody
tau
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380040658.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN104602708A (zh
Inventor
森启
富山贵美
松本洋一
江口广志
九里裕一
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Public University Legal Person Osaka
Teijin Pharma Ltd
Teijin Ltd
Original Assignee
Teijin Pharma Ltd
Osaka City University PUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd, Osaka City University PUC filed Critical Teijin Pharma Ltd
Publication of CN104602708A publication Critical patent/CN104602708A/zh
Application granted granted Critical
Publication of CN104602708B publication Critical patent/CN104602708B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380040658.9A 2012-05-31 2013-05-30 痴呆症治疗药或预防药 Active CN104602708B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012124336 2012-05-31
JP2012-124336 2012-05-31
PCT/JP2013/065090 WO2013180238A1 (ja) 2012-05-31 2013-05-30 認知症治療剤又は予防剤

Publications (2)

Publication Number Publication Date
CN104602708A CN104602708A (zh) 2015-05-06
CN104602708B true CN104602708B (zh) 2021-11-30

Family

ID=49673425

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380040658.9A Active CN104602708B (zh) 2012-05-31 2013-05-30 痴呆症治疗药或预防药

Country Status (30)

Country Link
US (3) US20150183854A1 (https=)
EP (2) EP2857039B1 (https=)
JP (3) JP5971659B2 (https=)
KR (2) KR102133610B1 (https=)
CN (1) CN104602708B (https=)
AR (1) AR091218A1 (https=)
AU (2) AU2013268364B2 (https=)
BR (1) BR112014029566A2 (https=)
CA (1) CA2875205C (https=)
CY (1) CY1122530T1 (https=)
DK (1) DK2857039T3 (https=)
ES (2) ES2973070T3 (https=)
HR (1) HRP20192267T1 (https=)
HU (1) HUE046919T2 (https=)
IL (1) IL235899B (https=)
LT (1) LT2857039T (https=)
ME (1) ME03587B (https=)
MX (1) MX361128B (https=)
MY (1) MY172458A (https=)
NZ (1) NZ630536A (https=)
PH (1) PH12014502669B1 (https=)
PL (1) PL2857039T3 (https=)
PT (1) PT2857039T (https=)
RS (1) RS59802B1 (https=)
RU (1) RU2657438C2 (https=)
SG (2) SG10201805410XA (https=)
SI (1) SI2857039T1 (https=)
TW (2) TWI700296B (https=)
WO (1) WO2013180238A1 (https=)
ZA (1) ZA201409186B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120244174A1 (en) 2011-01-31 2012-09-27 Intellect Neurosciences Inc. Treatment of tauopathies
JP6457263B2 (ja) * 2011-05-20 2019-01-23 オリゴメリックス インコーポレイテッド タウプロテアーゼ組成物および使用方法
PL2857039T3 (pl) * 2012-05-31 2020-05-18 Osaka City University Środek terapeutyczny lub środek profilaktyczny na otępienie
SG10201708959WA (en) 2012-07-03 2017-11-29 Univ Washington Antibodies to tau
TWI734975B (zh) * 2014-06-27 2021-08-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
US20190224339A1 (en) * 2016-04-29 2019-07-25 Voyager Therapeutics, Inc. Compositions for the treatment of disease
JP6785372B2 (ja) * 2016-09-30 2020-11-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性分子の機能分析のためのｓｐｒに基づく二重結合アッセイ
SG11201907422RA (en) 2017-02-17 2019-09-27 Denali Therapeutics Inc Anti-tau antibodies and methods of use thereof
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
AR112600A1 (es) 2017-05-30 2019-11-20 Teijin Pharma Ltd Anticuerpo anti-receptor de igf-i
EP3691639B1 (en) 2017-10-02 2023-11-15 Merck Sharp & Dohme LLC Chromane monobactam compounds for the treatment of bacterial infections
AU2018352308B2 (en) 2017-10-16 2025-06-05 Eisai R&D Management Co., Ltd. Anti-tau antibodies and uses thereof
EP4471152A3 (en) 2018-04-06 2025-03-26 Teijin Pharma Limited Spns2 neutralizing antibody
EP3819378A4 (en) 2018-07-04 2022-09-14 Aichi Medical University OLIGONUCLEOTIDES FOR CONTROL OF TAU SPLICING AND THEIR USES
CN110028583B (zh) * 2019-05-07 2020-09-11 温州医科大学 抗Tau抗体及其在治疗阿尔茨海默病、创伤性脑损伤中的应用
GB2585252A (en) 2019-07-05 2021-01-06 Gen2 Neuroscience Ltd Tau epitope and binding molecules
JP7429404B2 (ja) * 2019-08-06 2024-02-08 慶應義塾 タウ関連疾患モデルの製造方法
US20220365102A1 (en) 2019-09-30 2022-11-17 Nipro Corporation Tau protein detection method using blood sample as test specimen
IL296611A (en) * 2020-03-19 2022-11-01 Vascular Biosciences Car peptide for improved coronavirus survival
CA3183835A1 (en) 2020-06-25 2021-12-30 Jeanne E. Baker High affinity antibodies targeting tau phosphorylated at serine 413
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
KR20250069606A (ko) 2022-09-15 2025-05-19 보이저 테라퓨틱스, 인크. 타우 결합 화합물
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010144711A3 (en) * 2009-06-10 2011-05-26 New York University Immunological targeting of pathological tau proteins

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS587390B2 (ja) 1975-03-11 1983-02-09 ツキシマキカイ カブシキガイシヤ ア−クヨウセツホウホウ
JP3587390B2 (ja) 1994-03-17 2004-11-10 タカラバイオ株式会社 リン酸化アミノ酸誘導体及びリン酸化ペプチド合成方法
US20020086009A1 (en) * 1996-03-13 2002-07-04 Koichi Ishiguro Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same
US20080199471A1 (en) * 2002-03-01 2008-08-21 Bernett Matthew J Optimized cd40 antibodies and methods of using the same
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US20070280935A1 (en) * 2006-04-07 2007-12-06 Bernd Bohrmann Antibody that recognizes phosphorylated peptides
EP2028932A4 (en) * 2006-06-16 2011-10-12 Vitruvean Llc TAU AND AMYLOID FOREIGNER FRAGMENT EXPRESSING TRANSGENIC FLY
UA107571C2 (xx) * 2009-04-03 2015-01-26 Фармацевтична композиція
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
US20120244174A1 (en) * 2011-01-31 2012-09-27 Intellect Neurosciences Inc. Treatment of tauopathies
TR201102696U (tr) * 2011-05-27 2011-06-21 Turhal Sal�H Bağlantısız hareketli ürün reklam standı.
PL2857039T3 (pl) * 2012-05-31 2020-05-18 Osaka City University Środek terapeutyczny lub środek profilaktyczny na otępienie
JP2018139530A (ja) * 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010144711A3 (en) * 2009-06-10 2011-05-26 New York University Immunological targeting of pathological tau proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain;Allal Boutajangout et al.;《JOURNAL OF NEUROCHEMISTRY》;20110801;658-667 *

Also Published As

Publication number Publication date
MY172458A (en) 2019-11-26
CY1122530T1 (el) 2021-01-27
PH12014502669B1 (en) 2020-02-19
HUE046919T2 (hu) 2020-04-28
PH12014502669A1 (en) 2015-02-02
JPWO2013180238A1 (ja) 2016-01-21
TW202041532A (zh) 2020-11-16
ZA201409186B (en) 2015-12-23
AU2018200413B2 (en) 2019-10-17
US20220340646A1 (en) 2022-10-27
AU2013268364B2 (en) 2018-02-08
KR102133610B1 (ko) 2020-07-14
AU2013268364A1 (en) 2014-12-18
MX2014014187A (es) 2015-06-04
RS59802B1 (sr) 2020-02-28
JP5971659B2 (ja) 2016-08-17
US20200148753A1 (en) 2020-05-14
EP2857039A1 (en) 2015-04-08
JP2018111716A (ja) 2018-07-19
RU2014153099A (ru) 2016-07-20
SG10201805410XA (en) 2018-08-30
HK1210031A1 (en) 2016-04-15
CN104602708A (zh) 2015-05-06
IL235899A0 (en) 2015-01-29
ME03587B (me) 2020-07-20
NZ630536A (en) 2017-03-31
PT2857039T (pt) 2020-01-07
CA2875205C (en) 2021-07-20
HRP20192267T1 (hr) 2020-03-20
CA2875205A1 (en) 2013-12-05
EP2857039B1 (en) 2019-11-20
JP6620829B2 (ja) 2019-12-18
ES2973070T3 (es) 2024-06-18
JP6406678B2 (ja) 2018-10-17
EP3662931A1 (en) 2020-06-10
US20150183854A1 (en) 2015-07-02
EP3662931B1 (en) 2023-12-06
TWI700296B (zh) 2020-08-01
EP2857039A4 (en) 2015-08-26
AR091218A1 (es) 2015-01-21
DK2857039T3 (da) 2019-12-16
MX361128B (es) 2018-11-28
IL235899B (en) 2019-03-31
AU2018200413A1 (en) 2018-02-08
PL2857039T3 (pl) 2020-05-18
SI2857039T1 (sl) 2020-03-31
KR20150027098A (ko) 2015-03-11
BR112014029566A2 (pt) 2017-07-25
LT2857039T (lt) 2020-03-10
TWI777183B (zh) 2022-09-11
KR102208283B1 (ko) 2021-01-26
JP2016147902A (ja) 2016-08-18
KR20200029619A (ko) 2020-03-18
SG11201407878VA (en) 2015-01-29
WO2013180238A1 (ja) 2013-12-05
RU2657438C2 (ru) 2018-06-13
TW201410705A (zh) 2014-03-16
ES2763361T3 (es) 2020-05-28

Similar Documents

Publication Publication Date Title
CN104602708B (zh) 痴呆症治疗药或预防药
RU2760334C2 (ru) Моноклональные антитела к альфа-синуклеину для предотвращения агрегации тау-белка
JP7012004B2 (ja) シヌクレイノパチーの治療のための薬剤、使用および方法
JP7204235B2 (ja) 活性型α－シヌクレインに結合する抗体
JP2018139530A (ja) 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
TW202400643A (zh) 神經退化性疾病之治療劑
HK40031828B (en) Therapeutic agent or prophylactic agent for dementia
HK40031828A (en) Therapeutic agent or prophylactic agent for dementia
HK1210031B (zh) 痴呆症治疗药或预防药
WO2025047850A1 (ja) 神経変性疾患の治療剤
CN119212728A (zh) 用于处理神经病的组合物和方法
CN118804929A (zh) 神经变性疾病的治疗剂
HK40113703A (zh) 神经变性疾病的治疗剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1210031

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address

Address after: Osaka, Japan

Patentee after: Public University Legal Person Osaka

Patentee after: TEIJIN PHARMA Ltd.

Address before: Osaka City, Osaka of Japan

Patentee before: OSAKA CITY University

Patentee before: TEIJIN PHARMA Ltd.

CP03 Change of name, title or address
TR01 Transfer of patent right

Effective date of registration: 20230424

Address after: Osaka, Japan

Patentee after: Public University Legal Person Osaka

Patentee after: TEIJIN Ltd.

Address before: Osaka, Japan

Patentee before: Public University Legal Person Osaka

Patentee before: TEIJIN PHARMA Ltd.

TR01 Transfer of patent right